New study tests if MRI-Guided biopsy spots aggressive prostate cancer better than standard method
NCT ID NCT03234556
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial compares two biopsy methods for diagnosing prostate cancer in African American and white men with elevated PSA. One group gets a standard 12-core random biopsy, the other gets an MRI-guided fusion biopsy. The goal is to see which method more accurately detects clinically significant prostate cancer (Gleason score 7 or higher). The study involves 288 participants and is not recruiting new patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could show that MRI-guided biopsy is more accurate than standard biopsy for finding aggressive prostate cancer, potentially reducing unnecessary biopsies.
What could go wrong
This is a phase II trial with 288 participants, so results may not apply to all men. The study only includes African American and white men, limiting generalizability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH STATUS UNKNOWN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Hospital Vattikuti Urology Institute
Detroit, Michigan, 48202, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States